Enoxaparin sodium

Generic Name: Enoxaparin sodium

Brand Names: Lovenox, Inhixa

Drug Type: Small Molecule

CAS Number: 9005-49-6

Unique Ingredient Identifier: E47C0NF7LV

Background: Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated heparin, without increasing the risk of serious bleeding.

Indication: Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.

Enoxaparin is also indicated in the prophylaxis of DVT in abdominal surgery, hip replacement, knee replacement, or medical patients with severely restricted mobility during acute illness. Additionally, enoxaparin is indicated for the inpatient treatment of DVT with or without pulmonary embolism and the treatment of outpatient DVT without pulmonary embolism.

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina

Associated Therapies: Percutaneous Coronary Intervention (PCI)

Clinical Trials

Low-Dose Enoxaparin in Psoriasis

Not Applicable

Not yet recruiting

Conditions: Psoriasis

Interventions: Drug: Subcutaneous Enoxaparin

First Posted Date: 2024-05-16

Last Posted Date: 2024-05-16

Lead Sponsor: Zagazig University

Target Recruit Count: 30

Registration Number: NCT06416566

Thromboprophylaxis in Lower Limb Immobilisation

Phase 3

Recruiting

Conditions: Injury Leg
Thrombosis

Interventions: Drug: Enoxaparin Injectable Solution
Drug: Rivaroxaban
Drug: Tinzaparin Injectable Solution
Drug: Apixaban
Drug: Dalteparin Injectable Solution
Drug: Fondaparinux Injectable Product

First Posted Date: 2024-04-17

Last Posted Date: 2024-11-29

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 10044

Registration Number: NCT06370273

Locations: 🇬🇧
Epsom and St Helier University Hospitals NHS Trust, Carshalton, Surrey, United Kingdom
🇬🇧
Barts Health NHS Trust, London, United Kingdom
🇬🇧
Northern Care Alliance NHS Foundation Trust, Manchester, United Kingdom

Enoxaparin for Preventing the Radical Artery Occlusion After the Transradial Access Hepatic Arterial Infusion Chemotherapy

Phase 2

Recruiting

Conditions: Radial Artery Occlusion

Interventions: Drug: Placebo
Drug: Subcutaneous enoxaparin sodium

First Posted Date: 2024-03-05

Last Posted Date: 2024-03-08

Lead Sponsor: Zhongshan Hospital (Xiamen), Fudan University

Target Recruit Count: 156

Registration Number: NCT06293287

Locations: 🇨🇳
Zhongshan Hospital, Fudan University (Xiamen Branch), Xiamen, Fujian, China

A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery

Phase 2

Not yet recruiting

Conditions: Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery

Interventions: Drug: SHR-2004
Drug: Enoxaparin Sodium Injection; Rivaroxaban Tablets

First Posted Date: 2024-01-23

Last Posted Date: 2024-01-23

Lead Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd

Target Recruit Count: 350

Registration Number: NCT06220123

Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

Phase 2

Recruiting

Conditions: Knee Arthroplasty, Total

Interventions: Drug: KN060 Low
Drug: KN060 Middle
Drug: KN060 Hight
Drug: Enoxaparin

First Posted Date: 2023-12-26

Last Posted Date: 2023-12-29

Lead Sponsor: Suzhou Alphamab Co., Ltd.

Target Recruit Count: 240

Registration Number: NCT06180889

Locations: 🇨🇳
Shanghai Sixth People's Hospital, Shanghai, Shanghai, China

Lovenox With Aspirin in Thawed Blastocyst Transfer

Phase 4

Recruiting

Conditions: Infertility, Female

Interventions: Drug: Lovenox
Drug: Aspirin
Procedure: Embryo transfer

First Posted Date: 2023-11-18

Last Posted Date: 2024-02-21

Lead Sponsor: Fertility Center of Las Vegas

Target Recruit Count: 130

Registration Number: NCT06133803

Locations: 🇺🇸
Fertility center of Las Vegas, Las Vegas, Nevada, United States

Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery

Phase 2

Completed

Conditions: Thromboembolism

Interventions: Drug: Enoxaparin

First Posted Date: 2023-11-07

Last Posted Date: 2024-07-19

Lead Sponsor: University of Utah

Target Recruit Count: 60

Registration Number: NCT06118957

Locations: 🇺🇸
University of Utah, Salt Lake City, Utah, United States

Effectiveness & Safety of Ovine Enoxaparin Sodium to Originator Enoxaparin in Non-ST-Segment Elevation Acute Coronary Syndrome (NSTEACS) Patients: a Multicenter, Non-randomized, Open-label, Non-inferiority Trial

Phase 4

Recruiting

Conditions: Safety Issues
Effect of Drug

Interventions: Drug: Enoxaparin sodium injection

First Posted Date: 2023-11-02

Last Posted Date: 2023-11-02

Lead Sponsor: PT Bio Farma

Target Recruit Count: 220

Registration Number: NCT06114641

Locations: 🇮🇩
RSUP Dr.Sardjito, Yogyakarta, Yogyakarta, D.I.Yogyakarta, Indonesia
🇮🇩
RSUP Prof. Dr. I.G.N.G Ngoerah, Bali, Bali, Indonesia
🇮🇩
RS Jantung dan Pembuluh Darah Harapan Kita, Jakarta, Jakarta, DKI Jakarta, Indonesia

D2 Versus D3 Dissection in Laparoscopic Right Hemicolectomy

Not Applicable

Not yet recruiting

Conditions: Anastomotic Leakage
Lymph Node Disease
Blood Transfusion
Blood Loss
Survival
Intensive Care

Interventions: Drug: Enoxaparin 40 Mg/0.4 mL Injectable Solution
Procedure: LAPAROSCOPIC RIGHT HEMICOLECTOMY procedure (intervention)
Drug: Levofloxacin 500mg
Procedure: LAPAROSCOPIC RIGHT HEMICOLECTOMY procedure (Conventional)